Credit Suisse analyst Michael Morabito says he spoke with Intercept regarding the weakness in the shares, which he has attributed to negative competitor comments. Management reiterated its commercial outlook has not changed and maintains that while the company does not anticipate a bolus of patients at launch like what was seen for HCV, it does see a long period of steady growth in NASH and is confident in the long-term commercial outlook for obeticholic acid, he adds. Morabito believes the weakness will be short-lived and that Intercept shares are likely to return to their prior levels. He has an Outperform rating on the shares. In afternoon trading, the stock has dropped almost 7% to $74.52.